Publications by authors named "Kenzou Akagi"
Article Synopsis
- A rare case of a gastric gastrointestinal stromal tumor (GIST) was reported in a 58-year-old male, who had a history of duodenal GIST resected 9 years prior.
- Following anemia-related admission, a CT scan revealed a large stomach tumor over 10 cm, leading to extensive surgical intervention including subtotal gastrectomy and splenectomy.
- The pathological examination confirmed the tumor as a high-risk gastric GIST, and the patient has been successfully treated with imatinib since surgery, with no recurrence observed in the last 2 years.
Objective: To examine the effect of S-1 adjuvant chemotherapy on muscle volume after curative gastrectomy in gastric cancer patients.
Patients: Forty-eight gastric cancer patients (31 men and 17 women) who underwent curative gastrectomy (distal gastrectomy: n=37, and total gastrectomy: n=11) between April 2010 and July 2011 were enrolled in this study. Sixteen patients underwent S-1 adjuvant chemotherapy (S-1 group) for 1 year after the operation, and 32 patients did not (NT group).
A 41-year-old man who had non-small cell lung cancer invading his right 3rd, 4th and 5th ribs with hilum lymph node swelling(cT3N1M0, cStage III A), received chemoradiation therapy, cisplatin(CDDP)/docetaxel, and 2 Gy/Fr of irradiation prior to surgery. But the therapy was discontinued due to interstitial pneumonitis on day 24, during 28 Gy of radiation. At that time, a PET-CT scan revealed the accumulation of FDG in the primary tumor, hilar lymph node, and one of the ipsilateral axillar lymph nodes, in which cancer cell presence was proven by aspiration needle cytology.
View Article and Find Full Text PDFBackground: Capecitabine is an established therapy for metastatic breast cancer. In Japan, a 4 weekly regimen is often used, but data for this schedule in the first-line setting are lacking.
Methods: Metastatic breast cancer patients who had received no chemotherapy for recurrent disease received capecitabine 825 mg/m(2) twice daily, on days 1-21 of a 28-day cycle until disease progression or unacceptable toxicity.